Compare Axogen Inc (AXGN) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs Prologis Inc — how do they compare? Axogen Inc trades at $44.44 (market cap $2.60B), while Prologis Inc trades at $134.72 (market cap $128.14B). The key difference: Prologis Inc is far larger — about 49.3× Axogen Inc's market cap, and Prologis Inc pays a 3.17% dividend while Axogen Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Axogen Inc for 19 Days and Prologis Inc for 101 Days on average.
| AXGN | PLD | |
|---|---|---|
Market Cap | $2.60B | $128.14B |
Volume | 1,124,697 | 7,640,823 |
Sector | Health | Real Estate |
52-Week High | $51.73 | $149.96 |
52-Week Low | $15.59 | $111.23 |
Typical Hold Time | 19 Days | 101 Days |
Enterprise Value | $2.50B | $162.88B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $44.23, down 2.33% today, with a bullish technical signal from moving averages but neutral oscillators. Revenue grew 23.1% year-over-year in Q2 2026 to $69.7 million, though the company posted a net loss. Recent developments include a $200 million acquisition of BioCircuit Technologies and a $208.7 million public offering to fund growth, expanding its nerve repair portfolio.
The outlook is mixed: strong analyst support (84% buy rating) and a $53.20 price target suggest upside, but persistent losses and high valuation ratios pose risks. Execution on acquisitions and path to profitability are critical for sustained gains amid competitive and regulatory pressures in the medical device sector.
Prologis (PLD) trades at $134.84, down 0.25% on the day, with a bearish technical signal but strong fundamentals. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $1.13 surpassing expectations. Revenue growth is steady, projected at $9.2B for 2026, and the company maintains high occupancy and leasing activity. A dividend of $1.07 is scheduled for September 2026, supporting income appeal.
Outlook is mixed: analyst consensus favors Buy with a $155.15 price target, implying 15% upside, but technical indicators signal near-term pressure. Risks include rising debt levels and market volatility. The stock's valuation metrics like P/E of 30.03 suggest premium pricing, requiring sustained growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
